Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02712060

Enrollment

Registered

2016-03-17

Start date

2016-03-31

Completion date

2017-05-31

Last updated

2017-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ehler's Danlos Syndrome, Obstructive Sleep Apnea

Keywords

Ehlers-Danlos Syndrome, Obstructive Sleep Apnea, Prevalence, Children, Pediatric, Adolescents

Brief summary

Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group of inherited connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. EDS features such as genetically related cartilage defects, craniofacial abnormalities and increased pharyngeal collapsibility have been proposed to cause obstructive sleep apnoea (OSA). There is evidence from studies based on questionnaires that EDS patients might be more frequently affected by OSA and sleep disturbances than the general population. However, the actual prevalence of OSA in children and adolescents with EDS is unknown. The primary objective of this study is to assess the prevalence of OSA in children and adolescents with EDS (25) compared to a matched control group (25). The secondary objective of this pioneer study is to assess the quality of life in children and adolescents in EDS in comparison to healthy children and adolescents.

Detailed description

Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group of inherited connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. EDS features such as genetically related cartilage defects, craniofacial abnormalities and increased pharyngeal collapsibility have been proposed to cause obstructive sleep apnoea (OSA). There is evidence from studies based on questionnaires that EDS patients might be more frequently affected by OSA and sleep disturbances than the general population. However, the actual prevalence of OSA in children and adolescents with EDS is unknown. The primary objective of this study is to assess the prevalence of OSA in children and adolescents with EDS compared to a matched control group. The secondary objective of this pioneer study is to assess the quality of life in children and adolescents in EDS in comparison to healthy children and adolescents.

Interventions

OTHERNo intervention

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* Informed consent * Diagnosis of Ehlers-Danlos Syndrome (not for control group)

Exclusion criteria

* Moribund or severe disease prohibiting protocol adherence * Continuous positive airway pressure treatment for OSA during sleep study * Physical or intellectual impairment precluding informed consent or protocol adherence * Pregnant patients

Design outcomes

Primary

Measure	Time frame
Prevalence of OSA in children and adolescents with EDS	up to 12 months

Secondary

Measure	Time frame
Quality of life in children and adolescents with EDS	up to 12 months

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026